Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
| 0.149 | |
| 0.149 | |
| - | |
| 0.149 | |
| 0.149 | |
| 0.116-0.343 | |
| 43 532 K | |
| 292 M | |
| 23 305 K | |
| 1.43 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of Next Science Limited (ASX:N...
Highlights In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log reductions in planktonic (free-floating) bacteria and 4-log to 8-log reductions in biofilm bacteria (colonies of bacteria) XPER...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
